First Trust Capital Management’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

First Trust Capital Management’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,106,378	Closed	-$12M	–	185
2023 Q3	$12M	Hold	1,106,378	–	–	0.66%	40
2023 Q2	$11.8M	Buy	1,106,378 +406,078	+58%	+$4.27M	0.7%	49
2023 Q1	$7.31M	Buy	700,300 +550,300	+367%	+$5.7M	0.32%	97
2022 Q4	$1.53M	Hold	150,000	–	–	0.08%	239
2022 Q3	$1.51M	Buy	150,000 +50,000	+50%	+$500K	0.07%	296
2022 Q2	$994K	Buy	+100,000	New	+$993K	0.07%	257

First Trust Capital Management's BIOS Position: Q4 2023 in Review

First Trust Capital Management sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q4 2023, closing a stake of 1,106,378 shares — an estimated $12M sold.

First Trust Capital Management first reported a position in BIOS in Q2 2022 and held it in 6 quarters. The position peaked at $12M in Q3 2023. 0 funds tracked by Wall St. Rank hold BIOS as of Q4 2023.

First Trust Capital Management reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q4 2023 after selling out during the quarter.
First Trust Capital Management sold 1,106,378 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q4 2023, an estimated $12M.
First Trust Capital Management first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q2 2022 and held it in 6 quarters.
First Trust Capital Management's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $12M in Q3 2023.
0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q4 2023.

Based on First Trust Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.